东北制药 相关负责人日前在接受中国证券报记者采访时表示，质量是药企安身立命之本。在医药行业 迈向高质量发展的当下，公司全面聚焦质量能力提升，持续抓好质量体系建设和精益制造，打造全链条 质量控制体系，不断提高体系成熟度，以质量拓展市场、创造价值。下一步，公司将认真总结全国"质 量月"活动期间的好经验、好做法，以更强决心、更大力度进一步提升质量管理水平，推动公司转型升 级。 筑牢质量防线 近年来，东北制药通过控股鼎成肽源，快速切入特异性细胞免疫治疗技术领域，战略布局生物药新赛 道，加快形成新的竞争优势，分享市场增长红利。 面对日益多元的业务类型和愈加丰富的产品结构，东北制药强化质量管控，全面提升体系化管控能力， 打造覆盖从原物料采购、生产过程控制到产品出厂的全链条质量管理闭环体系。 "为从源头把控质量，公司质量部门牵头组建专项审计小组，日前奔赴全国13个省区市，对25家重点原 料供应商开展深度现场审计。"上述负责人表示，通过"现场核查+文件审查+人员访谈"三维联动模式， 审计小组对原料溯源、生产工艺、质量控制等关键环节深入检查，从上游供应链环节出发，为产品质量 筑牢坚固防线。 2025年版《中华人民共和国药典》自 ...

● 本报记者 宋维东 东北制药相关负责人日前在接受中国证券报记者采访时表示，质量是药企安身立命之本。在医药行业迈 向高质量发展的当下，公司全面聚焦质量能力提升，持续抓好质量体系建设和精益制造，打造全链条质 量控制体系，不断提高体系成熟度，以质量拓展市场、创造价值。下一步，公司将认真总结全国"质量 月"活动期间的好经验、好做法，以更强决心、更大力度进一步提升质量管理水平，推动公司转型升 级。 筑牢质量防线 东北制药是我国重要的药品生产与出口基地之一，业务主要覆盖化学制药、医药商业、医药工程、生物 医药等板块。公司拥有维生素类、抗感染类、生殖系统和性激素类、神经系统类、抗艾滋病类、消化道 类、麻精及含麻系列类、其他普药类、生物诊断试剂类、大健康领域等十大系列精品，400多种化学原 料药、医药中间体和制剂产品。 "为从源头把控质量，公司质量部门牵头组建专项审计小组，日前奔赴全国13个省区市，对25家重点原 料供应商开展深度现场审计。"上述负责人表示，通过"现场核查+文件审查+人员访谈"三维联动模式， 审计小组对原料溯源、生产工艺、质量控制等关键环节深入检查，从上游供应链环节出发，为产品质量 筑牢坚固防线。 2025 ...

中国经济网北京9月22日讯 向日葵(300111.SZ)今日开盘涨停，截至发稿报5.95元，涨幅19.96%。9 月5日，公司股价收报4.96元，涨幅11.96%。 公司昨晚披露关于披露本次交易相关预案暨公司股票复牌及一般风险提示性的公告，公司拟以发行 股份及支付现金的方式购买漳州兮璞材料科技有限公司100%股权、浙江贝得药业有限公司40%股权并 募集配套资金。根据深交所相关规定，经公司申请，公司A股股票自2025年9月8日（星期一）上午开市 起停牌；经申请，公司股票将于2025年9月22日（星期一）上午开市起复牌。 | | | 单位:万元 | | --- | --- | --- | | 资产负债表项目 | 2024年12月31日 | 2023年12月31日 | | 资产总额 | 47.792.97 | 48,500.49 | | 负债总额 | 13.605.34 | 15.699.74 | | 所有者权益合计 | 34.187.63 | 32,800.75 | | 利润表项目 | 2024 年度 | 2023 年度 | | 营业收入 | 33.036.87 | 33.594.76 | | 营业利润 | 1, ...

Core Viewpoint - Sunflower is planning a significant asset restructuring by acquiring controlling stakes in two companies, aiming to expand its business into the semiconductor materials sector while consolidating its pharmaceutical operations [1][9]. Group 1: Acquisition Details - The company announced plans to acquire controlling rights in Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd. through share issuance and/or cash payment [1]. - The transaction is expected to constitute a major asset restructuring and will not lead to a change in the actual controller of the company [1]. - The stock will be suspended from trading starting September 8, 2025, with the transaction plan to be disclosed within 10 trading days [1]. Group 2: Company Background and Transition - Founded in 2005, Sunflower initially focused on solar energy products but faced performance pressures due to cyclical fluctuations in the photovoltaic industry [6]. - The company has previously attempted to diversify, including a significant asset restructuring in 2019 that led to a 60% stake acquisition in Beid Pharmaceutical, marking its entry into the pharmaceutical sector [7]. - In March 2020, the company rebranded to Zhejiang Sunflower Health Technology Co., Ltd., focusing on the research, production, and sales of pharmaceuticals [7]. Group 3: Financial Performance - In the first half of 2025, the company reported revenues of approximately 144 million yuan, a year-on-year decline of 8.33%, and a net profit of only 1.16 million yuan, down 35.68% [12]. - The financial struggles have prompted the company to explore cross-industry transitions, with the semiconductor materials acquisition seen as a strategic move to leverage high-growth potential in the tech sector [15]. - The company's performance has been declining, with a net profit of 7.83 million yuan in 2024, reflecting a 64.01% year-on-year decrease [14].

截至2025年8月22日收盘，昂利康股价报50.56元，较前一交易日下跌1.56%。当日成交额达4.33亿元， 换手率为4.64%。 昂利康属于化学制药板块，公司主营业务为医药产品的研发、生产和销售。作为创新药概念股，公司产 品涵盖抗感染类、心血管类、消化系统类等多个治疗领域。 近期创新药行业迎来多项政策支持。国家医保局与卫健委7月初印发《支持创新药高质量发展的若干措 施》，提出增设商业健康保险创新药品目录，支持创新药进入医保目录和商业保险创新药品目录。此 外，创新药出海也取得进展，多家药企与跨国药企达成合作协议。 资金流向方面，8月22日昂利康主力资金净流入365.83万元，近五日主力资金净流入1.35亿元。 风险提示：股市有风险，投资需谨慎。 ...

Group 1 - As of August 21, 2025, Jiuzhou Pharmaceutical's stock price is 18.43 yuan, down 0.16 yuan or 0.86% from the previous trading day [1] - The trading volume on that day was 254,225 hands, with a transaction amount of 468 million yuan [1] - Jiuzhou Pharmaceutical focuses on the chemical pharmaceutical sector, primarily engaged in the research, production, and sales of active pharmaceutical ingredients and intermediates [1] Group 2 - The company's product range includes treatments for infections, cardiovascular diseases, and central nervous system disorders [1] - In the second quarter of 2025, the China-Europe Medical Health Fund reduced its holdings in Jiuzhou Pharmaceutical by 4.3884 million shares, although it remains one of the top ten circulating shareholders [1] - On August 21, 2025, the net outflow of main funds for Jiuzhou Pharmaceutical was 83.2752 million yuan, with a cumulative net outflow of 200 million yuan over the past five trading days [1]

Group 1 - On August 8, the stock price of Anglikang closed at 54.34 yuan, down 1.41 yuan or 2.53% from the previous trading day [1] - The opening price on the same day was 55.64 yuan, with a highest point of 57.25 yuan and a lowest point of 54.06 yuan, with a trading volume of 140,753 hands and a transaction amount of 777 million yuan [1] - Around 10:12 AM on August 8, Anglikang's stock price experienced a rapid rebound, increasing over 2% within 5 minutes, rising from 55.59 yuan to 56.1 yuan, with a transaction amount of 199 million yuan during this period [1] Group 2 - Anglikang operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of pharmaceutical products [1] - The company's product range includes treatments for various fields such as anti-infection, cardiovascular, and digestive systems [1] Group 3 - On August 8, the net outflow of main funds was 49.57 million yuan, with a cumulative net outflow of 296 million yuan over the past five trading days [1]